MPP-Home

en / fr

The Medicines Patent Pool and Pfizer sign licence for access to key data on investigational tuberculosis treatment sutezolid

The Medicines Patent Pool (MPP) announced a licence agreement with Pfizer to facilitate the clinical development of sutezolid, an investigational medicine for the treatment of tuberculosis (TB).

Five years on, 3.9 million people in the developing world have access to HIV treatment dolutegravir, thanks to access-oriented voluntary licensing agreements

Read the joint MPP-ViiV Healthcare press release on the occasion of the five-year anniversary of the signing of their licences on dolutegravir.

2018 Annual Report: Expanding Access to Public Health

We are pleased to present our 2018 Annual Report, which has as its theme, “Expanding Access to Public Health." Discover on how this is fundamental to the mission of the MPP.

The Medicines Patent Pool publishes framework for prioritising target medicines for in-licensing under its newly expanded mandate

The MPP published in May a prioritisation framework that outlines a precise methodology for assessing candidate medicines that could play a major role in the MPP’s expanded mandate into new disease therapies beyond HIV, hepatitis C and tuberculosis.

Who We Are

The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to, and facilitate the development of, life-saving medicines for low- and middle-income countries.

Vision & Mission

Our Model

Strategy

Governance & Team

Funding

Who We Work With

MedsPaL

The Medicines Patents & Licences Database

The MPP’s patents and licences database, MedsPaL, is a resource that provides information on the intellectual property status of selected HIV, hepatitis C, tuberculosis and other patented essential medicines in low- and middle-income countries.

Additional information and disclaimers

Transparency

All MPP licences are publicly available in their entirety on our website. This is unprecedented in the pharmaceutical field.

Licence Overview

Update on Progress of Sublicensees

Projections

MPP in Numbers

Hover over the numbers to find out more

10 patent holders with MPP signed agreements

26 million patient-years through MPP’s generic partners from January 2012 to June 2019

23 generic manufacturers and product developers sublicensed from the MPP

18 products licensed to the MPP

150+

150+ ongoing pharmaceutical development projects

87% to 91%

87% to 91% of people living with HIV in developing countries covered by the MPP adult licences

92 to 131

92 to 131 countries covered by MPP adults licences

1.23

1.23 billion dollars saved, from January 2012 to June 2019

Latest News

28 October 2019

The Medicines Patent Pool and Pfizer sign licence for access to key data on investigational tuberculosis treatment sutezolid

Geneva, 28 October 2019 — The Medicines Patent Pool (MPP) today announced a licence agreement with Pfizer to facilitate the clinical development of sutezolid, an investigational medicine for the treatment of tuberculosis (TB). The drug candidate, if further developed in combination with other drugs, could be used to more effectively treat patients diagnosed with TB, particularly multidrug-resistant TB (MDR-TB). “TB, especially MDR-TB, has become a health security threat and finding new treatments for patients is now an urgent global public health priority. We must accelerate progress if we aim to put an end to the epidemic by 2030,” said Charles Gore, Executive Director of the Medicines Patent Pool. “The licence agreement we just signed with Pfizer is key for any organisation willing to further develop sutezolid and make it available for people who need it the most, especially in low- and middle-income countries.” Pfizer is granting MPP a non-exclusive, worldwide and royalty-free licence allowing potent...

28 October 2019

Invitation to submit interest in a sublicence for sutezolid

Investigational Tuberculosis Candidate Sutezolid The Medicines Patent Pool (MPP) is currently inviting interested product developers to indicate an interest in a sublicence for investigational tuberculosis (TB) treatment sutezolid. Pfizer has granted MPP a non-exclusive, worldwide, royalty-free licence to any remaining patent rights and importantly, to the preclinical and clinical data developed by Pfizer through phase I and phase IIa*. The agreement allows sublicensees to develop, make, have made, use, file for regulatory approval, sell, import and export sutezolid for prevention and/or treatment of TB (including for multidrug-resistant TB) worldwide. The full text of the agreement can be found here. Per the licence’s terms and conditions, MPP seeks to grant sublicences to any entity that can demonstrate a willingness and capacity to further develop and commercialise the product and make the product widely available. MPP will also require any sublicensee to agree upon reasonable diligence requireme...

23 October 2019

G20 Health Ministers endorse the Medicines Patent Pool’s expansion to essential medicines

Geneva, 22 October 2019 – In a joint declaration published on 20 October 2019, the G20 Health Ministers gathered in Okayama, Japan drew attention to some major global health issues, including achieving Universal Health Coverage (UHC) by 2030 through “access to safe, effective, quality and affordable essential medicines and vaccines” as defined by the Sustainable Development Goals. In that context, they specifically mentioned their support of the Medicines Patent Pool (MPP) expansion to essential medicines. In 2018, at the request of the international community, MPP expanded its mandate beyond treatment for HIV, hepatitis C and tuberculosis to other essential medicines and in 2019, MPP published a prioritisation framework that outlines a precise methodology for assessing candidate medicines that could play a major role in MPP’s expanded mandate. “After the supportive mention of the G7 Health Ministers in May, we are honoured to receive support from the G20 Health Ministers and are committed to playing ou...

Videos

Unable to load video, please allow cookie

Endorsements

“We support the engagement of all relevant organizations, such as WHO, UNAIDS, Gavi, the Global Fund, and Unitaid and initiatives, including the recent expansion of the Medicines Patent Pool, in their work to improve access for all to safe, effective, quali...”

Unable to load twitter timeline, please allow cookie